The Truth About the FDA and CBD

Please do not reply to this message, as replies are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Cannabis Profits Daily. If you have any questions or would like to change free your email settings, please reference the contact information at the bottom of this email. [Cannabis Profits Daily] Thursday, March 14, 2019 [The Future of Cannabis & the FDA]( By Greg Miller Earlier this week, I [wrote a report]( about FDA Commissioner Scott Gottlieb resigning from his post. I encourage you to take a look at that if you haven't already, as I explain that his resignation should not be a sign to sell your investments. And it turns out that I was right... The new acting FDA Commissioner is Ned Sharpless, who previously served as Director of the National Cancer Institute. In 2015, the Cancer Institute found in a study that cannabis killed cancer cells in mice and rats. While I don't know Sharpless's personal views on cannabis, we at least know that he is aware of studies that show the medicinal benefits of marijuana. He is serving in an interim role for now, but I'm not going to lose sleep waiting for Gottlieb's full-time replacement. As I've said before, 2019 is the "Year of CBD." It doesn't matter who takes the reigns as the FDA Commissioner. However, I do understand that some comments from the FDA have a number of investors still worried about a crackdown on the [CBD industry](. It's true that there is going to be a discussion between the FDA and cannabis industry, but it's not going to be the war that some are trying to make it out to be. In fact, the FDA has shown that it's ready to help the CBD market grow. [So if you have any doubts, don't worry - I'm going to show you why CBD investments are still set to make you a ton of money...]( [Why We Aren't Worried About Scott Gottlieb's Resignation From the FDA]( [This Niche Cannabis Sector Will Outshine All Others in 2019]( [Ride the Cannabis Rally With These Four Stocks]( This Stock Could Soon Be a Billion-Dollar Behemoth Here at the Institute, we believe one thing to be fact: [Brands are the future of cannabis](. These tiny, soon-to-be-household names could unlock more wealth than any other cannabis industry in the game. And today, we uncovered [one under-the-radar cannabis stock]( that could soon balloon into a billion-dollar branding behemoth. And I'm here to tell you that the profit potential our analysts are now projecting for this tiny micro-cap cannabis stock is incredible. In fact, I had my team run the numbers twice just to make sure that they got everything right. We're [talking a potential double-digit, even triple-digit gain](, virtually overnight. Making this a cannabis stock recommendation you can't afford to miss out on. All you have to do is [click here]( for all of the details. The pharmaceutical industry has long held onto American investors by the teeth of its multibillion-dollar research claims. [Big Pharma's recently exposed blind spot]( just revealed a shocking reality for medicine - and for Capitol Hill. Congress is no longer viewing drugs and treatment options through rose-colored lenses...This federal bill endorses modern medicine. Diseases that were once deemed incurable - could soon be curable... with [this clinical startup]( at the head. Despite a previous lack of regulatory clarity, the industry now has Congress in its corner... And as we speak, this medical breakthrough is traveling on [its pathway towards FDA approval](. But make no mistake - this investment window could capsize with an overflow of venture capitalists as soon as the next major announcement is issued. The FDA is now key in hand. Keep a closer eye on it [by clicking the link below](. --------------------------------------------------------------- You are receiving this e-mail at {EMAIL}, as a part of your subscription. Remove your email from this list: [Unsubscribe]( © 2019 The National Institute for Cannabis Investors All Rights Reserved The National Institute for Cannabis Investors | 1125 N Charles Street | Baltimore, MD 21201 Toll Free: 866.260.0361; International: 410.777.8270 [Contact Customer Service](mailto:support@nicinvestors.com?subject=Cannabis%20Profits%20Daily%20Question) Website: []( Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This information may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The National Institute for Cannabis Investors, 1125 N Charles Street, Baltimore, MD 21201. [Privacy Policy]( | [Terms & Conditions](